Epilepsy Society responds to reports of medicine stockpiling in advance of Brexit
Media reports in recent weeks have indicated that some UK pharmaceutical companies are stockpiling medicines in preparation for a possible hard Brexit in 2019.
Tribunal overrules findings in case involving epilepsy drug
A decision by the Competition and Markets Authority to fine Pfizer and Flynn Pharma a total of £90m for overcharging for an epilepsy drug, has been remitted back to the CMA after a tribunal ruled against the government watchdog's decision.
Clare Pelham comments on new sodium valproate regulations
Our chief executive Clare Pelham, a member of the Commission on Human Medicines' Sodium Valproate Expert Working Group, commented on the news of the new regulations surrounding sodium valproate.
Charity tells health secretary new drug regulations could fail without public campaign
Epilepsy Society today welcomes new regulatory measures to stop babies being born with avoidable disabilities after being exposed to the drug, sodium valproate, in the womb.
Poster campaign raises awareness of epilepsy on public transport
This week, for the first time ever, epilepsy is featuring as part of a high profile poster campaign across London's underground and bus networks.
Epilepsy Society welcomes new measures to ensure no babies are exposed to sodium valproate during pregnancy
New measures announced to stop babies being exposed to valproate in the womb
Valproate medicines are available in the UK under brand names such as Epilim, Epival, Episenta, Convulex and Orlept
No girl or woman should stop taking valproate without first consulting her doctor.